OptimizeRx (NASDAQ:OPRX) Board Approves Stock Repurchase Plan

OptimizeRx (NASDAQ:OPRX) announced that its Board of Directors has authorized a stock repurchase program on Thursday, March 5th, RTT News reports. The company plans to buyback $10.00 million in shares. This buyback authorization allows the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

OPRX has been the topic of a number of recent analyst reports. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Stephens reduced their price target on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday. Roth Mkm decreased their price target on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday. B. Riley Financial reiterated a “buy” rating and set a $11.00 price objective (down from $28.00) on shares of OptimizeRx in a research report on Friday. Finally, Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.57.

OptimizeRx Price Performance

Shares of OPRX opened at $6.74 on Friday. OptimizeRx has a 1 year low of $3.99 and a 1 year high of $22.25. The business has a 50-day moving average of $10.52 and a 200-day moving average of $14.72. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05. The company has a market capitalization of $125.63 million, a price-to-earnings ratio of 25.92 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a return on equity of 10.81% and a net margin of 4.69%. As a group, equities research analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx News Roundup

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.